News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bavarian Nordic (BAVA.CO) Announces 2013 Full Year Results


3/19/2014 9:34:36 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

KVISTGAARD, Denmark, March 19, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today published its 2013 annual report. Revenue was DKK 1,213 million / USD 224 million (DKK 1,017 million / USD 188 million in 2012). The Group recorded a profit before tax of DKK 6 million / USD 1 million (DKK 49 million loss / USD 9 million loss in 2012). Revenue and results were in line with the expectations for the year. As planned, the Company delivered 7 million doses of IMVAMUNEĀ® to the U.S. in 2013, of which 1.4 million doses relate to the new contract that was entered in April 2013.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES